Advantame vs Yellow Dye 6: which is worse?

What is Advantame?

Advantame is the newest FDA-approved synthetic sweetener, approved in 2014. Like neotame, it is a structural derivative of aspartame but with a vanillin-derived substituent. It is approximately 20,000 times sweeter than sucrose — the most potent sweetener currently approved for food use in the US.

What is Yellow Dye 6?

Yellow Dye 6 (Sunset Yellow FCF) is a synthetic orange-yellow azo dye derived from petroleum. It produces a bright orange-yellow color and is structurally similar to Yellow 5 but produces a more orange shade. Its chemical formula is C16H10N2Na2O7S2.

Documented risks

Advantame: Advantame is the newest approved high-intensity sweetener with the least post-approval safety data. The FDA approval was based on extensive pre-market animal studies showing no significant toxicity, carcinogenicity, reproductive toxicity, or neurotoxicity at relevant doses. EFSA approved it for EU use in 2014, finding no safety concerns based on the submitted data. Like other synthetic sweeteners, advantame has not been studied for long-term effects in large human populations post-approval. The same gut microbiome and glucose tolerance concerns raised for other sweeteners (aspartame, sucralose, acesulfame K) have not been specifically studied for advantame, though the class-wide concerns are relevant. Given its 2014 approval date, independent long-term safety studies are still limited.

Yellow Dye 6: Yellow Dye 6 was included in the 2007 Lancet study (McCann et al.), which found that a mixture of six dyes including Yellow 6 and sodium benzoate significantly increased hyperactivity in children. EFSA confirmed the effect warranted mandatory warning labels in the EU. EFSA's 2009 re-evaluation examined animal carcinogenicity data and found some studies showing adrenal tumors in male mice at high doses. EFSA set an ADI of 2.5 mg/kg body weight — lower than Yellow 5's ADI of 7.5 mg/kg, reflecting greater concern. The review noted limitations in the available data. Impurity concerns: commercial batches of Yellow 6 have been found to contain aromatic amine impurities including benzidine and 4-aminobiphenyl — both IARC Group 1 human carcinogens. A 1992 CSPI analysis documented these impurities, citing them as reason for concern. A 2007 study in Toxicological Sciences found Yellow 6 altered zinc and iron biomarker levels in rat blood at high doses, raising mineral metabolism concerns. Human relevance at typical exposure is unclear. Hypersensitivity reactions including urticaria, rhinitis, and contact dermatitis are documented. Cross-reactivity with aspirin is reported similarly to Yellow 5. In April 2025, the FDA announced plans to phase out Yellow 6 with other petroleum-based dyes.